Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply

Type Journal Article Author Denis Y. Logunov Author Inna V. Dolzhikova Author Amir I. Tukhvatullin Author Dmitry V. Shcheblyakov URL https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31970-X/abstract Series Correspondence Volume 396 Issue 10256 Pages e54-e55 Publication The Lancet ISSN 0140-6736, 1474-547X Date 21/09/2020 Extra Publisher: Elsevier PMID: 32971043 Journal Abbr The Lancet DOI 10.1016/S0140-6736(20)31970-X Library Catalog www.thelancet.com Language English Abstract We thank Enrico Bucci and colleagues for their Correspondence about our open, non-randomised phase 1/2 studies of a recombinant adenovirus type 26 (rAd26) and recombinant adenovirus type 5 (rAd5) vector-based heterologous prime-boost COVID-19 vaccine from Russia.1 Short Title Safety and efficacy of the Russian COVID-19 vaccine